Abstract 423P
Background
Nodular, acral, and mucosal melanomas that represent non-cumulative sun damage lesions account for more than 60% of melanomas in Asia but comprise only 4% in Caucasians. The distinct spectrum of manifestations might influence the clinical course and outcomes. Factors associated with the prognosis of high-risk resected melanomas from Indonesia have not yet been previously reported.
Methods
Demographic, clinical, pathological characteristics of 82 melanoma patients who underwent complete resection in 2014-2019 were analyzed.
Results
Nodular melanoma (NM), mucosal melanoma (MM), and acral lentiginous melanoma (ALM) made up of 42.7% (n=35), 42.7% (n=35), and 14.2% (n=12) of cases, respectively. Most patients were diagnosed at advanced stages (76.8%, n=63 at Stage III-IV). For cutaneous melanomas, 89% (N=42) patients were found with Breslow’s tumor thickness more than 4 mm, 51% (N=24) with ulceration, 93% (N=43) with diameter more than 6 mm, 59% (N=28) with lymphovascular invasion, and 74% (N=35) with regional lymph node infiltration. In mucosal melanomas, 14.5% (N=5) were diagnosed with regional spread to lymph nodes and 77% cases (N=27) were found with regional infiltration beyond mucosa. Regional lymph node spread was associated with shorter overall survival (median survivals were 17 vs 23.4 months, Mantel-Cox test p=0.049). Patients diagnosed at T4 were also associated with poor overall survival (median survivals were 23 vs 32 months, Mantel-Cox test p=0.047).
Conclusions
Most melanoma patients in Indonesia were found as a higher risk for recurrence after the initial complete resection. Regional lymph node infiltration and thicker tumor (T4) were associated with poor prognosis. Early detection and advancement of treatment strategy are required to improve the survivals of melanoma patients in Indonesia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sumadi Lukman Anwar.
Funding
Universitas Gadjah Mada.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session
413P - South Korean real-world treatment patterns in patients with EGFRm NSCLC
Presenter: Jae Cheol Lee
Session: e-Poster Display Session
414P - Incidence and characteristics of lung cancer diagnosed after kidney transplantation at the National Kidney and Transplant Institute
Presenter: Adeline Gonzales
Session: e-Poster Display Session
415P - Real-world fusion landscape of RET gene fusions and its response to cabozantinib in Chinese non-small cell lung cancer (NSCLC) using next generation sequencing
Presenter: Chunwei Xu
Session: e-Poster Display Session
416P - A single institute study evaluating the additional benefit of blood NGS testing over conventional molecular testing in metastatic adenocarcinoma lung
Presenter: Rajashree Ashwath
Session: e-Poster Display Session
417P - Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
Presenter: Amit Kumar
Session: e-Poster Display Session
418P - All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
Presenter: Ullas Batra
Session: e-Poster Display Session
419P - Surgical treatment of malignant tumours and metastatic lesions of the chest wall
Presenter: Zhanat Pyssanova
Session: e-Poster Display Session
421P - A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
Presenter: Ming Gao
Session: e-Poster Display Session
422P - Response rate and time to progression after first line chemotherapy with cisplatin and adriamycin in patients with metastatic osteosarcoma at presentation
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session